Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-04-24 AGM Information
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
关于召开2024年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2024 Annual General Meeting (AGM) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting date, voting methods, agenda items to be discussed (such as the 2024 annual report, financial statements, profit distribution plan, and other reports), and registration procedures. The document does not contain the actual reports or financial data but refers to them being disclosed elsewhere (on the Beijing Stock Exchange website). The document length is 4246 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2025-04-24 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' and is issued by the company's board. It details the company's internal policy and procedures for managing public opinion and media relations, including organizational structure, responsibilities, and response measures. It is a governance-related internal policy document rather than a financial report, announcement of voting results, or regulatory filing. The document length is 3493 characters, which is relatively short but contains substantive content about governance practices. There is no indication of financial data, audit information, or meeting materials. Therefore, the document best fits the category of Governance Information (CGR).
2025-04-24 Chinese
2024年度独立董事述职报告（邵荣光）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2024 by an independent director of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the director's attendance at board and shareholder meetings, participation in audit committee meetings, communication with internal audit and accounting firms, protection of investor rights, training attended, and other supervisory activities. The content focuses on the independent director's duties, oversight, and governance role rather than presenting financial statements or audit opinions themselves. It is a detailed report on board/management activities and governance oversight rather than a financial report or audit report. Therefore, the document fits best under the category of Board/Management Information (MANG).
2025-04-24 Chinese
关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the delay of certain investment projects funded by raised capital. It details the background of the fundraising, the use of funds, reasons for project delays, and opinions from the board, supervisory committee, independent directors, and the sponsoring institution. The document is focused on the management and use of raised funds and the postponement of investment projects, not on financial results or earnings. It is a regulatory announcement related to capital use and project progress, not a full financial report or earnings release. The document length is 4244 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the status and changes related to the company's fundraising investment projects.
2025-04-24 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (audit firm) for the year 2024. It discusses the appointment, qualifications, and audit work performed by the accounting firm for the company's 2024 annual audit. It includes details about the audit firm's independence, audit procedures, and the company's assessment of the audit firm's performance. The document does not contain the actual audited financial statements or detailed financial data but is an assessment and report on the audit firm's work. The document length is short (1356 characters), and it is clearly an audit report or information about the audit process rather than the full annual report or financial statements. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-04-24 Chinese
董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (auditor) for the company's 2024 annual audit. It details the auditor's qualifications, the audit committee's oversight activities, and the evaluation of the auditor's performance for the 2024 annual audit. The document references the 2024 annual report audit but does not contain the annual report itself or financial statements. It is a standalone audit-related report focusing on the auditor's supervision and evaluation, which fits the category of an Audit Report / Information (AR). The document length is short (1699 characters), but it is not merely an announcement of a report publication; it contains substantive content about audit supervision. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.